Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | DGKA | P23743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3460109 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2HPGDHTTALDH1A1EPHX2 | |
| SCHEMBL13029835 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2HPGDHTTALDH1A1EPHX2 | |
| SCHEMBL3625357 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2HPGDHTTALDH1A1EPHX2 | |
| SCHEMBL16376362 | 0.99 | SMN1; SMN2 (0.43) | SMN1; SMN2HPGDHTTALDH1A1EPHX2 | |
| SCHEMBL20008754 | 0.99 | SMN1; SMN2 (0.43) | SMN1; SMN2HPGDHTTALDH1A1EPHX2 | |
| SCHEMBL17753479 | 0.99 | SMN1; SMN2 (0.43) | SMN1; SMN2HPGDHTTALDH1A1EPHX2 | |
| SCHEMBL24136289 | 0.94 | SMN1; SMN2 (0.41) | SMN1; SMN2HPGDHTTALDH1A1EPHX2 | |
| SCHEMBL915308 | 0.94 | SMN1; SMN2 (0.41) | SMN1; SMN2HPGDHTTALDH1A1EPHX2 | |
| SCHEMBL25962486 | 0.94 | SMN1; SMN2 (0.41) | SMN1; SMN2HPGDHTTALDH1A1EPHX2 | |
| SCHEMBL16018106 | 0.91 | ALDH1A1 (0.46) | SMN1; SMN2HPGDHTTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216714-A1 | NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | JAMES KENNETH D | 2010-08-26 | — | — | US | disclosed |
| US-20100216714-A1 | NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | JAMES KENNETH D | 2010-08-26 | — | — | US | disclosed |
| US-20100216714-A1 | NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | JAMES KENNETH D | 2010-08-26 | — | — | US | disclosed |
| EP-1569683-B1 | MODIFIED NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | BIOCON LTD (IN) | 2010-03-03 | — | — | EP | disclosed |
| EP-1569683-B1 | MODIFIED NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | BIOCON LTD (IN) | 2010-03-03 | — | — | EP | disclosed |
| US-7662773-B2 | which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure | BIOCON LIMITED (IN) | 2010-02-16 | — | — | US | disclosed |
| US-7662773-B2 | which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure | BIOCON LIMITED (IN) | 2010-02-16 | — | — | US | disclosed |
| US-7662773-B2 | which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure | BIOCON LIMITED (IN) | 2010-02-16 | — | — | US | disclosed |
| US-7648962-B2 | which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure | BIOCON LIMITED (IN) | 2010-01-19 | — | — | US | disclosed |
| US-7648962-B2 | which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure | BIOCON LIMITED (IN) | 2010-01-19 | — | — | US | disclosed |
| US-20080207505-A1 | Bna Conjugates and Methods of Use | JAMES KENNETH D | 2008-08-28 | — | — | US | disclosed |
| US-20080207505-A1 | Bna Conjugates and Methods of Use | JAMES KENNETH D | 2008-08-28 | — | — | US | disclosed |
| US-20080207505-A1 | Bna Conjugates and Methods of Use | JAMES KENNETH D | 2008-08-28 | — | — | US | disclosed |
| US-20060172933-A1 | Natriuretic compounds, conjugates, and uses thereof | BIOCON LIMITED (IN) | 2006-08-03 | — | — | US | disclosed |
| WO-2006076471-A2 | BNP CONJUGATES AND METHODS OF USE | NOBEX CORPORATION (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060074009-A1 | Natriuretic compounds, conjugates, and uses thereof | BIOCON LIMITED (IN) | 2006-04-06 | — | — | US | disclosed |
| WO-2005116655-A2 | NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | NOBEX CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-1569683-A2 | MODIFIED NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | Nobex Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040203081-A1 | Natriuretic compounds, conjugates, and uses thereof | BIOCON LIMITED (IN) | 2004-10-14 | — | — | US | disclosed |
| WO-2004047871-A2 | MODIFIED NATURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | NOBEX CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207505-A1 | Bna Conjugates and Methods of Use | NPR1, NPPA, NPR3 | SMN1; SMN2 368/4885HPGD 391/4885HTT 2112/4885 |
| US-20040203081-A1 | Natriuretic compounds, conjugates, and uses thereof | NPR1, NPPA, NPR3 | SMN1; SMN2 874/4885HPGD 194/4885HTT 659/4885 |
| US-20100216714-A1 | NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | NPR1, NPPA, NPR3 | SMN1; SMN2 307/4885HPGD 284/4885HTT 624/4885 |
| US-20060074009-A1 | Natriuretic compounds, conjugates, and uses thereof | NPR1, NPPA, NPR3 | SMN1; SMN2 307/4885HPGD 284/4885HTT 624/4885 |
| US-20060172933-A1 | Natriuretic compounds, conjugates, and uses thereof | NPR1, NPPA, NPR3 | SMN1; SMN2 307/4885HPGD 284/4885HTT 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.